Changes in Measurement Procedure from a Radioassay to a Microbiologic Assay Necessitate Adjustment of Serum and RBC Folate Concentrations in the U.S. Population from the NHANES 1988–2010

Christine M. Pfeiffer, Jeffery P. Hughes, Ramon A. Durazo-Arvizu, David A. Lacher, Christopher T. Sempos, Mindy Zhang, Elizabeth A. Yetley, and Clifford L. Johnson

National Center for Environmental Health, CDC, Atlanta, GA; National Center for Health Statistics, CDC, Hyattsville, MD; Department of Preventive Medicine and Epidemiology, Loyola University, Chicago, IL; and Office of Dietary Supplements, NIH, Bethesda, MD

Abstract
The NHANES measured serum and RBC folate concentrations by using a radioassay during prefortification (1988–1994) and postfortification (1999–2006) periods followed by the use of a microbiologic assay (MBA) from 2007–2010. The MBA produces higher concentrations than does the radioassay and is considered to be more accurate. To allow for accurate long-term trending (1988–2010), we evaluated different regression models (linear, piecewise linear, and fractional polynomial) to assay-adjust the radioassay results to be comparable to the MBA results. The data used to derive the regression models originated from 2 crossover studies in which the 2 assays were applied to a set of 325 serum and 171 whole-blood samples. Fractional polynomial regression of logarithmically transformed data provided the best fit for serum folate. Linear regression of logarithmically transformed whole-blood data provided an equally good fit compared with the other models and was the simplest to apply for RBC folate. Prefortification serum and RBC folate geometric mean concentrations increased after adjustment from 13.0 to 16.7 nmol/L and from 403 to 747 nmol/L, respectively. Postfortification serum folate concentrations increased from 30 to 43 nmol/L, and RBC folate concentrations increased from 600 to 1100 nmol/L after adjustment, with some variation across survey cycles. The presented regression equations allow the estimation of more accurate prevalence estimates and long-term trends in blood folate concentrations in the U.S. population by using results that are equivalent to the MBA. This information will be useful to public health officials in the United States who are dealing with folic acid fortification issues. J. Nutr. doi: 10.3945/jn.1.156901.

Introduction
The NHANES measured serum and RBC folate concentrations for >30 y to assess the folate status of the U.S. population. NHANES usually maintains the same assay over many survey periods and tightly controls the performance of the assay so that changes in concentrations over time are attributable to real differences in folate status and are not confounded by changes in assay. However, at times, changes in assays are unavoidable, whether due to the discontinuation of an assay or due to technological advances. From 1988 through 2006, folate status has been monitored in NHANES by use of a BR (Bio-Rad radioassay), but in 2007 the manufacturer discontinued its production. For NHANES 2007–2010, the CDC selected a traditional MBA (microbiologic growth assay) using Lactobacillus rhamnosus (formerly known as Lactobacillus casei) to measure serum and RBC folate levels.

It is known that the MBA produces substantially higher serum and RBC folate concentrations than does the BR. These assay differences pose challenges in data interpretation across NHANES survey periods. Data users need to be able to assess long-term trends in folate status before fortification and during 12 y after the introduction of fortification. If
assay differences are not accounted for, users cannot determine whether time trends show actual changes in folate status or are due, in whole or in part, to assay differences. A 2010 roundtable of experts discussed these and other NHANES folate and vitamin B-12 measurement issues, and “the roundtable agreed that an adjustment equation based on a crossover study was necessary for time-trend evaluations” (6). The adjustment of assay differences to assess the prevalence of inadequate folate status and trends over time has also been deemed necessary by previous expert panels reviewing folate biomarker data from NHANES II and III (3,7). An uninterrupted, continuous, and accurate assessment of the folate status of the U.S. population from pre–folic acid fortification to postfortification (1998 and later) is not only important to U.S. public health officials but also to international public health officials who often compare their country-specific survey results to the U.S. data. Some countries use the MBA to conduct folate population monitoring, and they could compare their postfortification data with the 2007–2010 U.S. data generated with the MBA. However, they also need to be able to compare their prefortification data with the U.S. prefortification data, all of which was generated by using the BR.

In this article we describe the derivation of assay adjustments for the U.S. pre- and postfortification blood folate concentrations generated by the BR in the NHANES 1988–1994 and 1999–2006 to make them comparable to the MBA used in the NHANES 2007–2010. This will allow the comparison of blood folate data across many NHANES survey years. We show the impact of the assay adjustment on population means and on the frequency distribution curves of serum and RBC folate. A separate article described the long-term trends in folate status of the U.S. population using MBA-equivalent data (8).

**Participants and Methods**

**Survey design and participants.** The NHANES collects cross-sectional data on the health and nutritional status of the civilian noninstitutionalized U.S. population by using a stratified, multistage probability sample designed to represent the U.S. population on the basis of age, gender, and race/ethnicity (9). The survey is conducted by the NCHS (National Center for Health Statistics) at the CDC and changed in 1999 from a previously periodic survey to a continuous survey with data released in 2-y cycles. The NHANES race/ethnicity categories are based on self-reported data. All respondents provided their informed consent, and the NHANES protocol was reviewed and approved by the NCHS Research Ethics Review Board.

**Laboratory methods.** Non-anticoagulated and EDTA whole-blood samples were collected in the NHANES Mobile Examination Center during 2007–2010 from participants aged ≥1 y (10,11). An aliquot of EDTA whole blood was diluted (1:11) with 1% ascorbic acid solution to generate a hemolysate for the RBC folate analysis. The serum and whole-blood hemolysate samples were frozen and shipped on dry ice to the National Center for Environmental Health laboratory at the CDC for folate analyses by MBA. A 96-well plate assay using chloramphenicol-resistant cryo-preserved *L. rhamnosus* was used with slight modifications from a previously published procedure (12,13): 5-methyltetrahydrofolic acid was used as calibrator, a robotic work station was used to dilute and dispense samples and reagents into the 96-well plate, 4 replicates were prepared per sample at 2 dilutions by using 0.5% sodium ascorbate (1:100 and 1:200 for serum and 1:140 and 1:280 for whole-blood hemolysate), and a polynomial regression (third degree) was used for curve fitting (14–16).

To verify the comparability of results over time, the laboratory used 3 levels of well-characterized in-house-prepared quality-control pools (serum and whole-blood hemolysate) in every assay, analyzed reference materials from the National Institute of Standards and Technology (SRM 1955–serum (17) and the U.K. National Institute for Biological Standards and Control [RM 03-178–serum (18) and RM 95-528–lyophilized whole-blood hemolysate (19)] several times a year, and participated regularly in the U.K. NEQAS Haematinsics scheme proficiency testing program (20). Long-term quality-control CV for serum folate were 5.9–10% at 6.67–56.8 nmol/L for NHANES 2007–2008 and 4.7–8.5% at 8.43–58.6 nmol/L for NHANES 2009–2010 (13,16). For RBC folate, CV were 8.0–14% at 402–1570 nmol/L for NHANES 2007–2008 and 7.3–8.2% at 421–898 nmol/L for NHANES 2009–2010 (15,16). The Bio-Rad Quantaphase I radioassay was used during 1988–1991 and the Quantaphase II was used during 1991–2006 (Bio-Rad Laboratories). The NCHS has applied appropriate assay adjustments to the 1988–1991 folate data before their public release to account for method differences between the Quantaphase I and II (3). The performance of the BR has been discussed in previous reports (2,21). Long-term CV were 4.0–7.0% for serum folate at 5.20–29.9 nmol/L and 4.0–6.0% for RBC folate at 143–1120 nmol/L (21).

**Statistical analyses.** Statistical analyses were performed by using SAS (version 9; SAS Institute, Inc.) and SUDAAN (version 9; RTI International) software. Fractional polynomial regressions were performed by using STATA (version 11.2; StataCorp). In each NHANES survey period we used sample weights to account for differential nonresponse or noncoverage and to adjust for planned oversampling of some groups. Analyses were limited to participants 4 y and older because NHANES III did not provide information below that age. The only participants excluded from our analyses were those for whom data were missing: the sample size for assay-adjusted serum folate in NHANES III changed from 23,361 to 23,259 because 2 participants had serum folate values <1 and the adjustment formula requires logarithmic transformation (which produces a negative number) and then calculating the square root; the sample sizes for unadjusted and assay-adjusted RBC folate differed in NHANES III and in survey cycles from 1999 to 2006 because the RBC folate adjustment formula used serum folate, RBC folate, and hematocrit, and sometimes one of these tests was missing for participants.

We examined the relationship between the BR and MBA method by using data from 2 crossover studies conducted with convenience samples from different blood banks, one for serum (4) and one for whole blood (5). After logarithmically transforming the data to address the skewness of the distribution, we evaluated several regression approaches including linear, piecewise linear, and fractional polynomial (22) to determine the best fit. We then applied the regression equations to the BR data in NHANES to generate MBA-equivalent data. We chose a “forward” approach (in which MBA is the predicted variable and BR is the independent variable) rather than a “backward” approach (in which BR is the predicted variable and MBA is the independent variable) for both serum and RBC folate data because the MBA method is considered a more accurate method (6,23) and the BR method is no longer available.

We calculated descriptive statistics (geometric mean, selected percentiles, and their SE) of unadjusted (BR data as measured) and mathematically adjusted (BR data adjusted to be MBA equivalent) serum and RBC folate concentrations for the prefortification (1988–1994) and postfortification period (1999–2006, by 2-y survey periods). For purposes of comparing the assay-adjusted postfortification data from 1999 to 2006 (generated with the BR and adjusted to the MBA) with the MBA data from 2007 to 2010, we also provided data for these newest 2 NHANES survey periods. We plotted frequency distribution curves for each analyte for unadjusted and assay-adjusted data for the prefortification (1988–1994) and postfortification (combining 2 survey periods at a time, i.e., 1999–2002, 2003–2006, and 2007–2010) periods.

**Results**

**Regression equations.** We used data from a serum folate crossover study performed between the BR and the MBA (4) to relate the 2 assays. We examined several regression methods beyond the piecewise linear model (with a predefined knot)
performed by Fazili et al. (4), including linear (least-squares), piecewise linear (using a grid search to find the knot), and fractional polynomial. In this crossover study (n = 325), the BR results were 29% lower than the MBA results. Each regression model gave a similar R² of −0.95, but the regression line to fit the data varied slightly among models, particularly at the tails of the distribution (Fig. 1A). The linear regression model tended to overpredict at the tails of the serum folate distribution. The piecewise linear regression model [with the predefined knot (not shown) or grid search defined knot] provided better estimates at the tails, which is important for the estimation of prevalence at low or high cutoffs. Upon visual inspection, the fractional polynomial regression method gave a slightly better fit than did the other regression approaches, especially at lower serum folate values. It resulted in the following equation that regressed BR serum folate results (nmol/L) to match MBA results (serum folate-adjusted, nmol/L) (9):

\[
\text{Serum folate}_{\text{adjusted}} = 10^{(0.0188 \cdot x^3 - 2.7109 \cdot x^{-1/2} + 3.8276)}
\]

where \( x = \log_{10}(\text{Serum folate}) \) (note: **designates exponential).

Data from a separate WBF (whole-blood folate) crossover study (5) were used to examine the same types of regression methods mentioned above. The BR results in this crossover study (n = 171) were 45% lower than the MBA results; however, there was a different relationship between the 2 assays depending on the MTHFR (5,10-methylenetetrahydrofolate reductase) C677T polymorphism. Whole-blood samples from persons with the T/T genotype showed a smaller difference between the 2 assays (31%) than did whole-blood samples from persons with the C/C and C/T genotypes (48%) (Fig. 1B). The reason for this was that the BR underrecovered 5-methyltetrahydrofolate acid and overrecovered some other folate forms, whereas the MBA showed close to complete recovery for the major folate forms (5). Regardless of the genotype, however, the difference between the 2 assays increased with increasing WBF concentration. Because MTHFR genotype information is not available for NHANES 1999–2010, we cannot use genotype-specific regression equations as recommended by Fazili et al. (5).

Using the crossover data for all genotypes, the linear, piecewise linear, and fractional polynomial regression models all gave a similar R² of −0.80 and a similar fit for the logarithmically transformed WBF data (Fig. 1C). We selected the linear regression model because it performed as well as the other models, even at the tails of the distribution, and was easier to apply. It resulted in the following equation that regressed BR WBF results (nmol/L) to match MBA results (WBF adjusted, nmol/L) (9):

\[
\text{WBF}_{\text{adjusted}} = 10^{(0.2204 + (1.017 \cdot x))}
\]

where \( x = \log_{10}(\text{WBF}) \). The regression line representing this equation lay below the regression lines for the C/C and C/T genotype and above the regression line for T/T genotype. At low folate concentrations, predicted values using this “all genotype” equation were similar to values using the C/C and C/T regression equations. At high folate concentrations, predicted values were lower compared with the C/C and C/T equations. Regardless of folate concentration, predicted values were always higher compared with the T/T equation.

Because NHANES data are reported as RBC folate, additional steps, as described below and in the analytic note released with the NHANES 2007–2008 (9) and 2009–2010 data (10), are necessary to calculate the MBA-equivalent concentrations:
TABLE 1  Descriptive statistics for weighted unadjusted and assay-adjusted serum and RBC folate concentrations in participants aged ≥4 y as measured by the BR and the MBA (NHANES 1988–2010)\textsuperscript{1}.

<table>
<thead>
<tr>
<th>NHANES survey cycle and assay</th>
<th>Data</th>
<th>Mean\textsuperscript{3}</th>
<th>5th</th>
<th>50th</th>
<th>95th</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>nmol/L</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Serum folate | | | | | |
|--------------|| | | | |
| 1988–1994 BR Unadjusted | 23,361 | 13.0 ± 0.3 | 4.6 ± 0.1 | 12.5 ± 0.3 | 39.0 ± 1.2 |
| Adjusted | 23,359 | 16.7 ± 0.5 | 3.3 ± 0.3 | 18.4 ± 0.5 | 56.8 ± 1.4 |
| 1999–2000 BR Unadjusted | 7411 | 31.7 ± 0.7 | 12.9 ± 0.5 | 32.1 ± 0.7 | 74.6 ± 1.7 |
| Adjusted | 7411 | 45.8 ± 1.0 | 19.2 ± 0.8 | 48.2 ± 1.0 | 93.4 ± 1.5 |
| 2001–2002 BR Unadjusted | 8242 | 29.1 ± 0.4 | 12.9 ± 0.4 | 29.4 ± 0.4 | 61.3 ± 1.1 |
| Adjusted | 8242 | 42.7 ± 0.6 | 19.2 ± 0.7 | 44.6 ± 0.6 | 80.8 ± 1.0 |
| 2003–2004 BR Unadjusted | 7692 | 27.4 ± 0.5 | 12.2 ± 0.3 | 27.0 ± 0.5 | 63.9 ± 1.5 |
| Adjusted | 7692 | 40.3 ± 0.7 | 17.8 ± 0.5 | 41.4 ± 0.7 | 83.3 ± 1.4 |
| 2005–2006 BR Unadjusted | 7639 | 27.9 ± 0.5 | 12.4 ± 0.4 | 27.7 ± 0.4 | 64.0 ± 2.0 |
| Adjusted | 7639 | 41.1 ± 0.7 | 18.1 ± 0.7 | 42.3 ± 0.6 | 83.5 ± 2.0 |
| 2007–2008 MBA Unadjusted | 7705 | 39.2 ± 0.9 | 14.7 ± 0.4 | 40.2 ± 1.0 | 92.6 ± 1.2 |
| Adjusted | 7705 | 57.9 ± 0.5 | 24.3 ± 0.4 | 57.2 ± 1.0 | 105.0 ± 1.3 |
| 2009–2010 MBA Unadjusted | 8184 | 37.9 ± 0.5 | 14.3 ± 0.4 | 38.7 ± 0.4 | 90.0 ± 1.3 |

| RBC folate | | | | | |
|--------------|| | | | |
| Adjusted | 22,846 | 747 ± 10 | 360 ± 6 | 734 ± 12 | 1630 ± 29 |
| 1999–2000 BR Unadjusted | 7491 | 636 ± 12 | 346 ± 9 | 626 ± 13 | 1190 ± 29 |
| Adjusted | 7393 | 1180 ± 24 | 639 ± 17 | 1170 ± 24 | 2250 ± 52 |
| 2001–2002 BR Unadjusted | 8336 | 627 ± 9 | 350 ± 7 | 620 ± 8 | 1180 ± 21 |
| Adjusted | 8220 | 1160 ± 17 | 645 ± 12 | 1150 ± 17 | 2200 ± 41 |
| 2003–2004 BR Unadjusted | 7700 | 585 ± 8 | 331 ± 7 | 575 ± 9 | 1090 ± 21 |
| Adjusted | 7618 | 1080 ± 16 | 609 ± 12 | 1070 ± 17 | 2070 ± 43 |
| 2005–2006 BR Unadjusted | 7751 | 616 ± 6 | 343 ± 4 | 603 ± 5 | 1170 ± 21 |
| Adjusted | 7578 | 1140 ± 11 | 630 ± 6 | 1120 ± 9 | 2200 ± 44 |
| 2007–2008 MBA Unadjusted | 7728 | 1120 ± 23 | 569 ± 11 | 1120 ± 24 | 2200 ± 59 |
| Adjusted | 8223 | 1040 ± 14 | 545 ± 8 | 1030 ± 15 | 2020 ± 51 |
| 2009–2010 MBA Unadjusted | 8184 | 1040 ± 14 | 545 ± 8 | 1030 ± 15 | 2020 ± 51 |

\textsuperscript{1} BR, Bio-Rad radioassay; MBA, microbiologic assay.
\textsuperscript{2} The sample size for adjusted serum folate in NHANES III changed from 23,361 to 23,359 because 2 participants had serum folate values <1 and the adjustment formula requires logarithmic transformation (which produces a negative number) and then calculating the square root. The sample sizes for unadjusted and adjusted RBC folate differed in NHANES III and in survey cycles from 1999 to 2006 because the RBC folate adjustment formula used serum folate, RBC folate, and hematocrit and sometimes one of these measurements was missing for participants.
\textsuperscript{3} Values are geometric means ± SE.
\textsuperscript{4} Values are percentile estimates ± SE.

1) The BR RBC folate results (nmol/L) have to be converted to BR WBF results (nmol/L) before adjustment to match MBA results: WBF = (RBC folate · HCT/100) + serum folate · [1 − (HCT/100)], using the HCT (hematocrit; %) and BR serum folate (nmol/L).

2) The BR serum folate results (nmol/L) have to be regressed by using the fractional polynomial regression equation to match MBA results (serum folate\textsubscript{adjusted}, nmol/L): serum folate\textsubscript{adjusted} = 10\textsuperscript{x × 0.0188} · x\textsuperscript{3.8276}, where x = log\textsubscript{10} serum folate.

3) Last, the adjusted WBF results (WBF\textsubscript{adjusted}, nmol/L) have to be back-converted to adjusted RBC folate results (RBC folate\textsubscript{adjusted}, nmol/L) by using adjusted serum folate (serum folate\textsubscript{adjusted}, nmol/L) and HCT results (%): RBC folate\textsubscript{adjusted} = [WBF\textsubscript{adjusted} − [serum folate\textsubscript{adjusted} · (1.0 − (HCT/100))]]/(HCT/100).

Blood folate concentrations before and after assay adjustments. Serum and RBC folate concentrations were much higher in 2007–2010 using the MBA method compared with previous postfortification years (1999–2006) that used the BR method (Table 1). However, after adjustment of the 1999–2006 BR data, all six 2-y survey periods produced similar geometric means and selected percentiles for serum and RBC folate. For serum folate, the effect of the assay adjustment was larger on the left tail (lower concentrations) and center of the distribution compared with the right tail (higher concentrations) of the distribution for each of the 4 postfortification survey periods. For RBC folate, the effect of the assay adjustment was similar throughout the entire distribution for the 4 survey periods.

As expected, assay adjustment of the prefortification data from 1988 to 1994 resulted in higher geometric means and selected percentiles, but serum and RBC folate concentrations were still significantly lower than in the postfortification data. As seen with the postfortification data, the effect of the assay adjustment was different across the entire distribution for serum folate but similar for RBC folate.

Frequency distribution curves for serum (Fig. 2) and RBC folate (Fig. 3) also showed that assay adjustment of the pre- and postfortification BR data changed the entire distribution to show higher concentrations. The assay-adjusted distribution curves for 1999–2006 were similar to the unadjusted 2007–2010 distribution curve produced by the MBA.
Discussion

This article describes how to adjust U.S. pre- and postfortification blood folate concentrations obtained with a defunct radioassay to make them comparable to the MBA and the impact of the adjustment on population means and on the frequency distribution curves of serum and RBC folate. The introduction of the U.S. folic acid fortification program in the late 1990s was an important public health intervention that required a careful impact assessment at the time and still requires continuous monitoring of population blood folate concentrations to ensure that neither folate inadequacy reemerges nor folate oversupply occurs in the general population and in at-risk groups. Monitoring biochemical indicators such as blood folate concentrations over time is superior to monitoring only dietary folate intake because it is not affected by several uncertainties in intake data that are difficult to measure (e.g., underestimation of intake, changing market composition of folate-fortified foods).

The ability to adjust the folate biomarker concentrations to MBA-equivalent data is also important from the perspective of interpreting prevalence results because the MBA is the method by which cutoffs for assessing inadequate folate status have been derived (23). It is also a generally accepted assay against which the accuracy of other assays is evaluated (6,23). Finally, the MBA used in NHANES 2007–2010 produces equivalent (±10%) results for serum folate compared with the CDC liquid chromatography–MS/MS method (2), which, in turn, has been shown to produce results equivalent to National Institute of Standards and Technology–developed liquid chromatography–MS/MS methods (17). The key to a strong biomarker monitoring program is the availability of accurate and precise laboratory methods that generate results that are consistent across laboratories, methods, and over time, as well as interpretable from the known biological relationship of commonly used cutoffs to inadequate status. These have long been recognized as necessary prerequisites to assessing population prevalence estimates and time trends in folate status (1,3,6,7).

Unfortunately, for decades the clinical folate community has had major problems with assays that readily lend themselves to clinical laboratory settings but that do not generate comparable results: in some cases, they suffer from poor precision or produce inaccurate results and undergo frequent reformulations by the manufacturer (24,25). Consequently, public health officials...
planning for NHANES had to face difficult decisions with regard to which folate assay to best choose for this important and unique population survey that generates reference data and prevalence estimates for the United States but is also a cornerstone for countries worldwide that may not afford to carry out their own national folate status assessment or may want to compare their data to U.S. data.

A recent article by Yetley and Johnson (1), which was written as part of proceedings from a 2010 roundtable of experts discussing NHANES folate and vitamin B-12 measurement issues, provides detailed background on the history of folate biomarker measurements in NHANES. The traditional folate MBA was chosen during the early NHANES surveys; however, poor precision and low throughput led to a reassessment of the applied technology (7). Radioassays became widely available in the 1980s and offered improved precision and throughput compared with the MBA (24). The Bio-Rad Quantaphase I radioassay, which was initially calibrated against the MBA, was used toward the end of NHANES II (1978–1980) and during the first phase of NHANES III (1988–1991). However, a recalibrated Bio-Rad Quantaphase II assay (using a spectrophotometrically verified folic acid calibrator) was introduced in 1993 and was used in the second phase of NHANES III (1991–1994) and in NHANES 1999–2006 (3). The recalibrated assay, although it provided excellent precision and stability, resulted in a 30% downward shift in measured folate concentrations and necessitated the use of adjusted cutoffs to assess folate inadequacy (3). In 2007 the manufacturer discontinued the BR, and NHANES 2007–2010 used a new version of the MBA, which is superior to older MBA in precision, stability, throughput, and user friendliness (14,25).

The excellent stability of the Quantaphase II BR over time has allowed public health officials to assess changes in population blood folate concentrations associated with the initiation of the U.S. folic acid fortification program (21). However, the differences in folate concentrations between the BR and MBA assays have led to questions about how to appropriately use folate cutoffs and how to compare data from these 2 assays. The regression equations developed in this study will help bridge the BR and MBA and allow continued long-term trending of blood folate concentrations in the U.S. population beyond the availability of the BR. Also, this study allows other studies that use the MBA to compare their data with those of the NHANES.

As with other statistical adjustments, regression equations have limitations. Depending on the regression model used, we observed a difference in fit mainly at the tails of the distribution. As discussed in the 2010 roundtable on “NHANES Monitoring of Biomarkers of Folate and Vitamin B-12 Status” (2), the tails of the distribution are a high priority for folate status assessment. We therefore chose the regression model that not only provided overall the best fit for the data but also provided the best fit at the tails of the distribution.

A second limitation of statistical adjustments is that a mean adjustment is applied, despite the fact that there is sample-to-sample variability. However, the higher the correlation is between the 2 methods, the better the quality of the statistical adjustment. For serum folate we obtained a high degree of correlation ($R^2 = 0.95$) in the crossover study between results produced by the BR and the MBA, which indicated that the major difference between the 2 assays was due to a systematic bias and that there was little random bias. The correlation was weaker ($R^2 = 0.80$) for WBF in the crossover study, which may be due to ≥2 factors. First, the analysis of WBF requires the hemolysis of RBC and the deconjugation of folate polygluta-

**Acknowledgments**

The authors acknowledge contribution from the following laboratory members: Daniel Rabinowitz, Neelima Paladugula, Bridgette Haynes, and Donna LaVoie (CDC National Center for Environmental Health). C.M.P., D.A.L., and C.T.S. designed the overall research project; C.M.P., J.P.H., R.A.D.-A., D.A.L., and C.T.S. conducted most of the research; C.M.P., J.P.H., and D.A.L. analyzed most of the data; and C.M.P. wrote the initial draft, which was modified after feedback from all coauthors, and had primary responsibility for content. All authors read and approved the final manuscript.

**Literature Cited**


